<!doctype HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<html>

<head>
<meta content="text/html; charset=windows-1252">
<meta content="en-us">
<meta name="GENERATOR" content="Microsoft FrontPage 6.0">
<meta name="ProgId" content="FrontPage.Editor.Document">
<title></title>
</head>

<body>

<p></p>
<center>
<p><b><font size="2">UNITED STATES<br>
SECURITIES AND EXCHANGE COMMISSION<br>
WASHINGTON, D.C. &nbsp;20549<br>
</font>
<br>
FORM 8-K</b></p>
<p align="center"><b>CURRENT REPORT<br>
Pursuant to Section 13 or 15(d) of the Securities Exchange Act
of 1934</b></p>
<p align="center"><br>
Date of Report (Date of earliest event reported) &nbsp;&nbsp;&nbsp;<u>April 11,
2008 (April 8, 2008)</u><br>
<br>
</p>
<table border="0" cellspacing="1" width="450">
  <tr>
    <td>
    <p align="center"><b><font size="5">KIMBALL INTERNATIONAL, INC.</font></b></td>
  </tr>
  <tr>
    <td><hr SIZE="1"></td>
  </tr>
  <tr>
    <td>
    <p align="center"><font size="2">(Exact name of registrant as specified in
    its charter)</font></td>
  </tr>
</table>
<p align="center"></p>
<center>
<table cellSpacing="0" width="624" border="0">
  <tr>
    <td width="33%">&nbsp;</td>
    <td width="33%">&nbsp;</td>
    <td width="33%">&nbsp;</td>
  </tr>
  <tr>
    <td>
    <p align="center">Indiana</td>
    <td>
    <p align="center">0-3279</td>
    <td>
    <p align="center">35-0514506</td>
  </tr>
  <tr>
    <td>
    <p align="center"></p>
    <hr width="90%" SIZE="1"></td>
    <td>
    <p align="center"></p>
    <hr width="48%" SIZE="1"></td>
    <td>
    <p align="center"></p>
    <hr width="90%" SIZE="1"></td>
  </tr>
  <tr>
    <td align="center"><font size="2">(State or other jurisdiction of</font></td>
    <td align="center"><font size="2">(Commission File</font></td>
    <td align="center"><font size="2">(IRS Employer Identification No.)</font></td>
  </tr>
  <tr>
    <td align="center"><font size="2">incorporation)</font></td>
    <td align="center"><font size="2">Number)</font></td>
    <td>&nbsp;</td>
  </tr>
</table>
<table cellSpacing="0" width="624" border="0">
  <tr>
    <td width="55%">&nbsp;</td>
    <td width="4%">&nbsp;</td>
    <td width="41%">&nbsp;</td>
  </tr>
  <tr>
    <td>
    <p align="center">&nbsp;</td>
    <td>&nbsp;</td>
    <td>
    <p align="center">&nbsp;</td>
  </tr>
  <tr>
    <td>
    <p align="center">1600 Royal Street, Jasper, Indiana</td>
    <td>&nbsp;</td>
    <td>
    <p align="center">47549-1001</td>
  </tr>
  <tr>
    <td>
    <p align="center"></p>
    <hr width="64%" SIZE="1"></td>
    <td>&nbsp;</td>
    <td>
    <p align="center"></p>
    <hr width="48%" SIZE="1"></td>
  </tr>
  <tr>
    <td align="center"><font size="2">(Address of principal executive offices)</font></td>
    <td>&nbsp;</td>
    <td align="center"><font size="2">(Zip Code)</font></td>
  </tr>
</table>
</center>
<p align="center">Registrant's telephone number, including area code &nbsp;&nbsp;<u>(812)
482-1600</u></p>
<table border="0" cellspacing="1" width="350">
  <tr>
    <td>
    <p align="center">Not Applicable</td>
  </tr>
  <tr>
    <td><hr SIZE="1"></td>
  </tr>
  <tr>
    <td>
    <p align="center"><font size="2">(Former name or former address, if changed
    since last report)</font></td>
  </tr>
</table>
</center>
<p align="left"><font size="2">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions (see General Instruction A.2.
below):</font></p>
<p align="left"><font size="2">[&nbsp;&nbsp; ] Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)</font></p>
<p align="left"><font size="2">[&nbsp;&nbsp; ] Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></p>
<p align="left"><font size="2">[&nbsp;&nbsp; ] Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></p>
<p align="left"><font size="2">[&nbsp;&nbsp; ] Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></p>
<p align="center">&nbsp;</p>
<p align="center">1</p>
<hr SIZE="1"><div style="page-break-before:always">
	<p></p>
	<p></p>
	<p></div>
<p align="left"><b>Item 2.05 Costs Associated with Exit or Disposal Activities</b><br>
<br>
Evolving customer preferences for Electronics Manufacturing Services (EMS)
operations in low-cost regions has prompted Kimball International, Inc. to
reevaluate its European facility strategy. On April 8, 2008, Kimball
International, Inc. (the &quot;Company&quot;) approved a plan to expand its European
automotive electronics capabilities and to establish a European Medical Center
of Expertise in Poznan, Poland. The Company presently has an operation in
Poznan. As part of the plan, the Company will consolidate its Electronics
facilities located in Longford, Ireland; Bridgend, Wales; and Poznan into a new,
larger facility in Poznan, which is expected to improve margins in the very
competitive EMS market. <br>
<br>
The existing Poland facility will not accommodate the additional production
space requirements for the products being transferred from the exited units
along with expected future sales growth in both automotive and medical markets. As a
result, on April 8, 2008, the Company signed a conditional agreement to sell the
facility that houses its current Poland operation for 15.5 million Euros or
approximately $24.0 million United States dollars (USD) based on an estimated
exchange rate of 0.645 Euros to one USD. The closing date for the transaction is
expected to occur before December 2008. The Company will recognize a total
pre-tax gain of approximately $18.0 million, of which $14.7 million is expected
to be recognized in the Company's second quarter fiscal year 2009 when the final
agreement is executed and the remaining pre-tax gain of $3.3 million will be
deferred over the approximately 43 months that the Company will lease back the
facility. The proceeds on the sale of the Poland building and an expected tax
benefit related to the exits will partially fund the consolidation
activities. The Poland operation expects to start production of select product
in the new facility beginning July 1, 2009, with all production, including
product transferred from Wales and Ireland, scheduled to be in the new facility
by December 2011.<br>
<br>
Under the Ireland portion of the plan, which is subject to consultation with
appropriate representatives of local employees regarding any redundancies,
production would cease at the Ireland facility during the quarter ending
December 31, 2008, and appropriate inventory and equipment will be relocated at
that time. Also under the plan, employees would be terminated in stages as
production is transferred. Miscellaneous wrap-up activities including
disposition of remaining equipment are expected to be completed by the end of
fiscal year 2009. The building for the Ireland operation is currently leased
with the lease expiring May 2009. <br>
<br>
The Bridgend, Wales, facility portion of the plan, which is subject to
consultation with appropriate representatives of local employees regarding any
redundancies, contemplates the movement of production to the new Poland facility
in phases, with the first move of production planned to occur during the
quarter ending March 31, 2009. The final move of production is planned to
occur during the quarter ending December 31, 2010. The move will occur in
phases due to longer qualification time in some markets for medical products and
the acquisition timeline for the new facility in Poland. Also under the plan,
employees would be terminated in stages as production is transferred and it is
expected that the remaining wrap-up activities will be complete by the end of
the quarter ending December 31, 2010. The building for the Wales operation is
currently leased with the lease expiring April 1, 2011.<br></p><p align="center">2</p>
<p align="center"></p>
<hr SIZE="1"><div style="page-break-before:always"></div>
The Company currently estimates that the pre-tax charges related to the
consolidation activities will be approximately, in millions, $13.6 consisting of
approximately $12.2 of severance and other employee costs, $0.6 of lease exit
costs, $0.4 of property and equipment non-cash asset impairment, and $0.4 of
other exit costs. Approximately $13.2 million of the total cost estimate is
expected to be cash expense, exclusive of proceeds from sale of equipment which
are expected to be approximately $0.2 million. The Company expects that 88%, 7%,
2%, and 3% of the restructuring costs will be recognized in the Consolidated
Statement of Income in the Company's fiscal years 2008, 2009, 2010, and 2011,
respectively, as most of the severance costs will be accrued at the date of the
approval of the plan. These estimates exclude the estimated gain on the sale of
the Poland building disclosed above. <br>
<br>
The pre-tax charges discussed above will be paid in a currency other than the
USD. Included in the estimate is 4.7 million of charges in British Pounds that
were converted based on an exchange rate of 0.5 British Pounds to one USD and
2.7 million of charges in Euros at 0.645 Euros to one USD. <br>
<br>
<b>Item 2.06 Material Impairments</b><br>
<br>
The information set forth above under Item 2.05 is incorporated by reference
into this Item 2.06. <br>
<br>
<b>Forward-Looking Statements</b><br>
Certain statements contained within this document are considered forward-looking
under the Private Securities Litigation Reform Act of 1995. These statements can
be identified by the use of words such as &quot;estimates,&quot; &quot;expects,&quot; &quot;anticipates,&quot;
and similar expressions. These forward-looking statements are subject to risks
and uncertainties including, but not limited to, general economic conditions,
foreign currency exchange rate fluctuations, or similar unforeseen events that
could cause actual results to differ materially from the forward-looking
statements.&nbsp;&nbsp; Cautionary statements regarding risk factors that could
have an effect on future performance of the Company are contained in the
Company's Annual Report of Form 10-K for the fiscal year ended June 30, 2007.<br>
&nbsp;</p>
<p align="center">3</p>
<p align="center"></p>
<hr SIZE="1"><div style="page-break-before:always"></div><center>
<p><b>SIGNATURES</b></p>
</center>
<p>Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized. </p>
<div align="right">
  <table cellSpacing="0" border="0" cellpadding="0">
    <tr>
      <td width="30">&nbsp;</td>
      <td width="300">&nbsp;</td>
    </tr>
    <tr>
      <td width="30">&nbsp;</td>
      <td width="300">KIMBALL INTERNATIONAL, INC.</td>
    </tr>
    <tr>
      <td width="30">&nbsp;</td>
      <td width="300">&nbsp;</td>
    </tr>
    <tr>
      <td width="30">&nbsp;</td>
      <td width="300">&nbsp;</td>
    </tr>
    <tr>
      <td width="30">
      <p align="center">By:</td>
      <td width="300">/s/ Robert F. Schneider</td>
    </tr>
    <tr>
      <td width="30">&nbsp;</td>
      <td width="300"><hr align="left" width="70%" SIZE="1"></td>
    </tr>
    <tr>
      <td width="30">&nbsp;</td>
      <td width="300">ROBERT F. SCHNEIDER<br>
      Executive Vice President, <br>
      Chief Financial Officer</td>
    </tr>
  </table>
</div>
<p><br>
Date: April 11, 2008</p>
<p align="center">4</p>
<hr size="1">

</body>

</html>
[{"type": "8-K", "sequence": "1", "filename": "form8k041108.htm", "description": "KIMBALL INTERNATIONAL, INC. FORM 8-K", "secsgml_size_bytes": 11624}]
{"company-data": {"conformed-name": "KIMBALL INTERNATIONAL INC", "cik": "0000055772", "assigned-sic": "2520", "irs-number": "350514506", "state-of-incorporation": "IN", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-03279", "film-number": "08752354"}, "business-address": {"street1": "1600 ROYAL ST", "city": "JASPER", "state": "IN", "zip": "47549", "phone": "8124821600"}, "mail-address": {"street1": "1600 ROYAL STREET", "city": "JASPER", "state": "IN", "zip": "47549"}, "former-company": {"former-conformed-name": "JASPER CORP", "date-changed": "19740826"}}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.  20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act
of 1934
Date of Report (Date of earliest event reported)
April 11,
2008 (April 8, 2008)
KIMBALL INTERNATIONAL, INC.
(Exact name of registrant as specified in
    its charter)
Indiana
0-3279
35-0514506
(State or other jurisdiction of
(Commission File
(IRS Employer Identification No.)
incorporation)
Number)
1600 Royal Street, Jasper, Indiana
47549-1001
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code
(812)
482-1600
Not Applicable
(Former name or former address, if changed
    since last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions (see General Instruction A.2.
below):
[   ] Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
[   ] Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[   ] Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[   ] Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1
Item 2.05 Costs Associated with Exit or Disposal Activities
Evolving customer preferences for Electronics Manufacturing Services (EMS)
operations in low-cost regions has prompted Kimball International, Inc. to
reevaluate its European facility strategy. On April 8, 2008, Kimball
International, Inc. (the "Company") approved a plan to expand its European
automotive electronics capabilities and to establish a European Medical Center
of Expertise in Poznan, Poland. The Company presently has an operation in
Poznan. As part of the plan, the Company will consolidate its Electronics
facilities located in Longford, Ireland; Bridgend, Wales; and Poznan into a new,
larger facility in Poznan, which is expected to improve margins in the very
competitive EMS market.
The existing Poland facility will not accommodate the additional production
space requirements for the products being transferred from the exited units
along with expected future sales growth in both automotive and medical markets. As a
result, on April 8, 2008, the Company signed a conditional agreement to sell the
facility that houses its current Poland operation for 15.5 million Euros or
approximately $24.0 million United States dollars (USD) based on an estimated
exchange rate of 0.645 Euros to one USD. The closing date for the transaction is
expected to occur before December 2008. The Company will recognize a total
pre-tax gain of approximately $18.0 million, of which $14.7 million is expected
to be recognized in the Company's second quarter fiscal year 2009 when the final
agreement is executed and the remaining pre-tax gain of $3.3 million will be
deferred over the approximately 43 months that the Company will lease back the
facility. The proceeds on the sale of the Poland building and an expected tax
benefit related to the exits will partially fund the consolidation
activities. The Poland operation expects to start production of select product
in the new facility beginning July 1, 2009, with all production, including
product transferred from Wales and Ireland, scheduled to be in the new facility
by December 2011.
Under the Ireland portion of the plan, which is subject to consultation with
appropriate representatives of local employees regarding any redundancies,
production would cease at the Ireland facility during the quarter ending
December 31, 2008, and appropriate inventory and equipment will be relocated at
that time. Also under the plan, employees would be terminated in stages as
production is transferred. Miscellaneous wrap-up activities including
disposition of remaining equipment are expected to be completed by the end of
fiscal year 2009. The building for the Ireland operation is currently leased
with the lease expiring May 2009.
The Bridgend, Wales, facility portion of the plan, which is subject to
consultation with appropriate representatives of local employees regarding any
redundancies, contemplates the movement of production to the new Poland facility
in phases, with the first move of production planned to occur during the
quarter ending March 31, 2009. The final move of production is planned to
occur during the quarter ending December 31, 2010. The move will occur in
phases due to longer qualification time in some markets for medical products and
the acquisition timeline for the new facility in Poland. Also under the plan,
employees would be terminated in stages as production is transferred and it is
expected that the remaining wrap-up activities will be complete by the end of
the quarter ending December 31, 2010. The building for the Wales operation is
currently leased with the lease expiring April 1, 2011.
2
The Company currently estimates that the pre-tax charges related to the
consolidation activities will be approximately, in millions, $13.6 consisting of
approximately $12.2 of severance and other employee costs, $0.6 of lease exit
costs, $0.4 of property and equipment non-cash asset impairment, and $0.4 of
other exit costs. Approximately $13.2 million of the total cost estimate is
expected to be cash expense, exclusive of proceeds from sale of equipment which
are expected to be approximately $0.2 million. The Company expects that 88%, 7%,
2%, and 3% of the restructuring costs will be recognized in the Consolidated
Statement of Income in the Company's fiscal years 2008, 2009, 2010, and 2011,
respectively, as most of the severance costs will be accrued at the date of the
approval of the plan. These estimates exclude the estimated gain on the sale of
the Poland building disclosed above.
The pre-tax charges discussed above will be paid in a currency other than the
USD. Included in the estimate is 4.7 million of charges in British Pounds that
were converted based on an exchange rate of 0.5 British Pounds to one USD and
2.7 million of charges in Euros at 0.645 Euros to one USD.
Item 2.06 Material Impairments
The information set forth above under Item 2.05 is incorporated by reference
into this Item 2.06.
Forward-Looking Statements
Certain statements contained within this document are considered forward-looking
under the Private Securities Litigation Reform Act of 1995. These statements can
be identified by the use of words such as "estimates," "expects," "anticipates,"
and similar expressions. These forward-looking statements are subject to risks
and uncertainties including, but not limited to, general economic conditions,
foreign currency exchange rate fluctuations, or similar unforeseen events that
could cause actual results to differ materially from the forward-looking
statements.   Cautionary statements regarding risk factors that could
have an effect on future performance of the Company are contained in the
Company's Annual Report of Form 10-K for the fiscal year ended June 30, 2007.
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
KIMBALL INTERNATIONAL, INC.
By:
/s/ Robert F. Schneider
ROBERT F. SCHNEIDER
Executive Vice President,
Chief Financial Officer
Date: April 11, 2008
4